Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.
Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine
Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Pollan L, Tohyama J, Liu Y, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Obunike J, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. Journal of Clinical Investigation 125(6), June 2015 Notes: [Accepted 4/2015]
Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ: Effects of Niacin, Statin, and Fenofibrate on Circulating PCSK9 Levels in Patients with Dyslipidemia. American Journal of Cardiology 115(2): 178-182, Jan 2015.
deGoma EM, Salavati A, Shinohara RT, Saboury B, Pollan L, Schoen M, Torigian DA, Mohler ER, Dunbar RL, Litt HI, Woo J, Rader DJ, Alavi A, Mehta NN: A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall
Inflammation Using Fluorodeoxyglucose Positron Emission Tomography. Acad Radiol 2015.
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH: Effects of Omega-3 Carboxylic Acids on Lipoprotein Particles and Other Cardiovascular Risk Markers in High-Risk Statin-Treated Patients with Residual Hypertriglyceridemia: A Randomized, Controlled, Double-blind Trial. Lipids in Health and Disease 14, 2015 Notes: Accepted 19 Aug 15.
Song W, Stubbe J, Ricciotti E, Dunbar RL, Rader DJ, FitzGerald GA: Systemic Eicosanoid and Cytokine Response to Niacin: Implications in HPS2-THRIVE Trial and Beyond [Poster Presentation] Journal of Clinical Lipidology 8(3): 309, June 2014 Notes: National Lipid Association 2014 Annual Scientific Sessions, May 1-4, 2014, Orlando, FL.
Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] Journal of Clinical Lipidology 8(3): 311, June 2014 Notes: National Lipid Association 2014 Annual Scientific Sessions, May 1-4, 2014, Orlando, FL.
Tuteja S, Duffy D, Dunbar RL, Movva R, Gadi R, Bloedon LT, Cuchel M
: Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia. Pharmacotherapy 34(3): 213–314, March 2014.
Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] JACC March 2014 Notes: 63rd Annual Scientific Session of the American College of Cardiology, Washington, DC, March 2014.
Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH: A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics 35(9): 1400-1411, September 2013.
deGoma,EM, Davis, MD, Dunbar, RL, Mohler, ER, III, Greenland, P, and French, B: Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 229(2): 517-523, Aug 2013.
back to top
Last updated: 08/20/2015
The Trustees of the University of Pennsylvania